Identification of Center

First Name, Last Name:		
Department:		
City:		
C		
Center information	· · · · · · · · · · · · · · · · · · ·	
	d to your Center have NTM been i	isolated in the last 12 months?
\Box 0		
□ 1-5		
□ 6-10		
□ 11-15		
□ 16-20		
□ >20		
Do you have a dedicated microbio	ology laboratory exist at your Inst	titution?
□ Yes		
\square No		
☐ If yes, indicate laborat	cory's name:	_
2) Does the microbiology labora	atory at your Institution perform a	cid fast bacilli (AFB) typing?
□ Yes		
□ No, but AFB typing is	performed in another Center	
□ No, AFB typing is not	performed	
3) If you answered yes to the pri	or question:	
	_	iscussing with the microbiologist)
□ Number of NTM isola	ated in the last 12 months:	
4) In which microbiological sam	uple have NTM been isolated? (inc	dicate, if known, also the % of
the total number of isolations)	
	Yes/No	%
Sputum		

Bronchial aspirate			
Lung biopsy			
Lymphonode biopsy/trans			
bronchial needle aspiration			
(TBNA)			
Bronchoalveolar Lavage			
(BAL)			
Other (please specify):		number of diagnosis)	
3) which is the nave been isola	ted? (If known, also indicate the n		
Mycobacterium avium	Yes/No	N.	
complex			
Mycobacterium Kansasii			
Mycobacterium Xenopi			
Mycobacterium Abscessus			
Mycobacterium Chelonae			
Wycobacterium encionae			
Other (please specify):			
Features of patients in whom N	TM have been isolated		
6a) Gender			
☐ Male (%):			
☐ Female (%):			
6a.i) Indicate, if known, the % o	f the total number of female paties	nts per age group:	
□ < 20-year-old (%):			
· · · · · · · · · · · · · · · · · · ·			

6a.1	11)	Indicate, if known, the % of the total number of male patients per age group:
		< 20-year-old (%):
		20-40-year-old (%):
		40-60-year-old (%):
		>60-year-old (%):
6b)	Sn	noking history (indicate the % of the total number of patients)
		Smokers (%):
		Never smokers (%):
		Former smokers (%):
	Pe	Indicate, if known, number of pack/years (p/y) for smokers: rcentage of HIV patients on the total number of patients (%):
6c)	Pe	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients)
6c) 6d)	Pe	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients) COPD (%):
6c) 6d)	Pe	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients) COPD (%): Asthma (%):
6c) 6d)	Per Co	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients) COPD (%): Asthma (%): Bronchiectasis (%):
6c)	Pe.	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients) COPD (%): Asthma (%):
6c)	Per Co	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients) COPD (%): Asthma (%): Bronchiectasis (%):
6c) 6d)	Per Co	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients) COPD (%): Asthma (%): Bronchiectasis (%): Lung cancer (%):
6c)	Pe	rcentage of HIV patients on the total number of patients (%): oncomitant diseases (% of the total number of patients) COPD (%): Asthma (%): Bronchiectasis (%): Lung cancer (%): Past history of tuberculosis (%):

7) Chest CT radiological pattern (indicate the type and site of lesions)

	Yes/No	%	Site 1*	Site 2*	Site 3*
Solid nodules					
Cavitated					
nodules					
Tree-in-bud					
Bronchiectasis					

MYCONOS - MYCObacteria not Tuberculous Observational Italian Survey Questionnaire on Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in non-Cystic Fibrosis patients *Answer options: Right Upper Lobe, Middle Lobe, Right Lower Lobe, Left Upper Lobe, Left Lower Lobe Other lesions (specify): 8) Which diagnostic-therapeutic criteria do you follow?

☐ American Thoracic Se	ociety (ATS) guidelines 2007	
-	cify):	
- Other guidennes (spec	Ciry)	
9) Relationship between clinical patients with NTM isolation)		
	Number	%
a) Clinically significant		
(isolation + disease)		
b) Non-clinically significant		
(colonization or contaminants)		
c) Indeterminate		
(including unknown and/or		
uncertain)		
10a) What percentage of clinical	ly significant patients (patients at	point 9a) was initiated to treatment
10b) Specify, if known, the perce	entage of clinically significant sub	jects (isolation + disease)
according to the type of NTM iso	plated:	
☐ Mycobacterium aviur	n complex (%):	
□ Kansasii (%):		
□ Xenopi (%):		
☐ Abscessus (%):		
☐ Chelonae (%):		
□ Other (%):		

10c) How long is the tin	ne between NTM Pulmo	onary Disease diagn	osis and treatment initiation?
☐ Maximum numb	er of days:		
☐ Minimum numbe	er of days:		
11) Does your microbiol	logy laboratory perform	sensitivity tests to a	antibiotics?
□ Yes			
\square No			
12) Referring to the type	e of NTM, what antibiot	ic did you choose?	
Drug 1*	Drug 2*	Drug 3*	Drug 4*
Mycobacterium avium c	complex		
Mycobacterium Kansasi	ii		
Mycobacterium Xenopi			
Other NTM (specify): _			
*Answer options: list of	antibiotics		
13) Adjuvant surgical th	erapy has been perform	ed?	
□ Yes			
\square No			
\Box If yes, specify, if	f known, the number of	cases:	
14a) Do you have patier	nts on therapy for at leas	t 6 months?	
□ Yes			
\square No			
☐ If yes, specify, if	f known, the number of	cases:	
14b) Patients' outcome a	after treatment:		

	Sputum conversion without recurrence or new infection (%):				
	NTM Persistence (%): Sputum conversion followed by true relapse (confirmation on genotypic analysis) (%):				
			(0.1)		
☐ Sputum conversion followed by presumed relapse (%):					
	-	•	(different type of NTM or same type but wi		
	different genotype) (%)	:			
15)	Other concomitant/adju	vant theranies (in additi	on to antihiotics):		
13)	Other concomitant/adju	vant incrapies (in additi	on to antibiotics).		
		Yes/No	9/0		
Respin	ratory physiotherapy				
Bronc	hodilator therapy				
Other	inhaled therapies				
Muco	lytic agents				
Other	(Specify)				
1 () D-	4: 4 C-11				
10) Pa	tient follow-up:				
	Outpatient clinic				
	Day Service				
	Day Hospital				
	Other (please specify):				
	dicate problems or issues	occurred during the dia	agnostic process and/or treatment:		
17) In	p		.O F		
17) In	Microbiological tests				
17) In	Microbiological tests Patients compliance				
17) In	Patients compliance	to treatment			
17) In	_				

MYCONOS - MYCObacteria not Tuberculous Observational Italian Survey